Serologic assessment of yellow fever immunity in the rural population of a yellow fever-endemic area in central Brazil

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 46, Issue 2, 2013, Pages 166-171

  Machado, Vanessa Wolff ^a   Vasconcelos, Pedro Fernando da Costa ^b   Silva, Eliana Vieira Pinto ^b   Santos, João Barberino ^a  

^a UNIVERSITY OF BRASILIA   (Brazil)

^b INSTITUTO EVANDRO CHAGAS   (Brazil)

Author keywords

Goi s; Luzi nia; Vaccine protection; Yellow fever

Indexed keywords

YELLOW FEVER VACCINE;

ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ARTICLE; BRAZIL; CHILD; CONTROLLED STUDY; ENDEMIC DISEASE; FEMALE; HEALTH SERVICE; HEALTH SURVEY; HUMAN; IMMUNIZATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRESCHOOL CHILD; RISK REDUCTION; RURAL POPULATION; SCHOOL CHILD; SEROLOGY; VACCINATION; VIRUS NEUTRALIZATION; VIRUS PLAQUE; YELLOW FEVER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BRAZIL; CHILD; CHILD, PRESCHOOL; ENDEMIC DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; RURAL POPULATION; SEROEPIDEMIOLOGIC STUDIES; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS; YOUNG ADULT;

EID: 84877944690     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/0037-8682-0007-2012     Document Type: Article

References (31)

1. Franco O. História da febre amarela no Brasil. Departamento Nacional de Endemias Rurais. Rio de Janeiro: Ministério da Saúde; 1969
2. Vasconcelos PFC. Febre amarela: reflexões sobre a doença, as perspectivas para o Século XXI e o risco da reurbanização. Rev Bras Epidemiol 2002; 5: 244-258
3. Santos JB. Inquérito clínico epidemiológico no surto de febre amarela de 1973, em 19 Municípios no Brasil Central. Anais do XIII Congresso da Sociedade Brasileira de Medicina Tropical e II Congresso da Sociedade Brasileira de Parasitologia. Brasília, Distrito Federal; 1977. 300p.
4. Pinhero FP, Travassos-da-Rosa APA, Moraes MA, Almeida Neto JC, Camargo S, Filgueiras FP. An epidemic of yellow fever in Central Brazil, 1972-1973. I. Epidemiological studies. Am J Trop Med Hyg 1978; 27:125-32
5. Ministério da Saúde. Casos de febre amarela, Brasil, Grandes Regiões e Unidades Federadas. 1990-2010. Serviço de Vigilância Sanitária. Brasília: Ministério da Saúde; 2010. [Cited 2012 January 12]. Available from: http://portal.saude.gov. br/portal/arquivos/pdf/tabela_1_fa_2010.pdf.
6. Instituto Brasileiro de Geografia e Estatística (IBGE) [Internet]. Censo Demográfico 2010. Brasília: IBGE; 2010. [Cited 2012 January 12]. Available from: www.ibge.gov.br/.
7. Deane LM, Ferreira Neto JA. Malária de macacos no Estado de Goiás, Brasil: encontro de guaribas, Alouatta caraya, infectados com Plasmodium brasilianum. Rev Inst Med Trop São Paulo 1973; 15:107-111
8. Ministério da Saúde. Manual de vigilância de epizootias em primatas nãohumanos. Brasília, Distrito Federal: Secretaria de Vigilância em Saúde; 2005
9. Stefano I, Sato HK, Pannuti CS, Omoto TM, Mann G, Freire MS, et al. Recent immunization against measles does not interfere with the sero-response to yellow fever vaccine. Vaccine 1999; 17:1042-1046
10. Lang J, Zuckerman J, Clarke P, Barret P, Kirkpatrick C, Blondeau C. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines. Am J Trop Med Hyg 1999; 60:1045-1050
11. Monath TP, Fowler E, Johnson CT, Balser J, Morin MJ, Sisti M, et al. An inactivated cell-culture vaccine against yellow fever. N Engl J Med 2011; 364:1326-1333
12. Lwanga SK, Lemeshow S. Sample size determination in health studies. A practical manual. 1st. ed. Geneva: World Health Organization; 1991
13. Vasconcelos PFC. Febre amarela. Rev Soc Bras Med Trop 2003; 36:275-293
14. Almeida Netto JC. Aspectos clínicos e fisiopatológicos da febre amarela. Rev Pat Trop 1991; 20:43-50
15. Ministério da Saúde. Situação da febre amarela no Brasil, Fundação Nacional de Saúde. Bol Eletr Epid 2001; 2:1-3. [Cited 2012 January 12]. Available from: http://portal.saude.gov.br/portal/arquivos/pdf/ano01_n02_fa_sit_epid_br.pdf.
16. Ministério da Saúde. Dados do Programa Nacional de Imunizações (PNI) 2010. [Cited 2012 September 3]. Available from: http://tabnet.datsus.gov.br/cgi/tabcgi. exe?pni/CNV/CPNIGO.def/.
17. Pinheiro FP, Travassos-da-Rosa APA, Moraes MAP. An epidemic of yellow fever in Central Brazil, 1972-1973. II. Ecological studies. Am J Trop Med Hyg 1981; 30:204-211
18. Moreno ES, Marques D, Figueira G, Fred J, Almeida RD, Albernaz RK, et al. Inquérito de cobertura vacinal e evento adverso à vacina de febre amarela no Município de Buri São Paulo, Brasil, 2009. BEPA 2009; 6. [Cited 2012 January 12]. Available from: http://www.cve.saude.sp.gov.br/agencia/bepa71_inquerito.htm.
19. Niedrig M, Lademann M, Emmerich P, Lafrenz M. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health 1999; 4:867-871
20. Niedrig M, Kursteiner O, Herzog C, Sonnenberg K. Evaluation of an indirect immunofluorescence assay for detection of immunoglobulin M (IgM) and IgG antibodies against yellow fever virus. Clin Vaccine Immunol 2008; 15:177-181
21. Melo AB, Silva MPC, Magalhães MCF, Gil LHVG, Carvalho EMF, Braga-Neto UM, et al. Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil. Am J Trop Med Hyg 2011; 85:739-747
22. Kay A, Chen LH, Sisti M, Monath TP. Short report: yellow fever vaccine seroconversion in travelers. Am J Trop Med Hyg 2011; 85:748-749
23. Monath TP, Nichols R, Archambault WT, Moore L, Marchesani R, Tian J, et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 2002; 66:533-541
24. Hepburn MJ, Kortepeter MG, Pittman PR, Boudreau EF, Mangiafico JA, Buck PA, et al. Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine. Vaccine 2006; 24:2843-2849
25. Collaborative Group for Studies With Yellow Fever Vaccine. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program. Vaccine 2007; 25:3118-3123
26. Camacho LAB, Freire MS, Leal MLF, Aguiar SG, Nascimento JP, Iguchi T, et al. Collaborative Group for the Study of Yellow Fever Vaccines. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. Rev Saude Publica 2004; 38:671-678
27. Meyer Jr HM, Hostetler Jr DD, Bernhein BC, Rogers NG, Lambin P, Chassary A, et al. Response of Volta children to jet inoculation of combined live measles, smallpox and yellow fever vaccines. Bull World Health Organ 1964; 30: 783-794
28. Wheelock EF, Sibley WA. Circulating virus, interferon and antibody after vaccination with the 17-D strain of yellow fever virus. N Engl J Med 1965; 273:194-198
29. Petralli JK, Merigan TC, Wilbur JR. Circulation interferon after measles vaccination. N Engl J Med 1965; 273:198-201
30. Belmusto-Worn VE, Sanchez JL, McCarthy K, Nichols R, Bautista CT, Magil AJ, et al. Randhomized double-blind phase III, pivotal field trial of the comparative immunogenicity, safety and tolerability of two yellow fever 17D vaccines (Arilvax, and YF-Vax) in healthy infants and children in Peru. Am J Trop Med Hyg 2005; 72:189-197
31. Grupo Colaborativo do Programa Nacional de Imunizações para o Estudo da Soroconversão pela Vacina contra Febre Amarela. Immunogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children younger than 2 year-old: a randomized, double-blind study. In: World Society for Pediatric Infectious Diseases. Thailand (Bangkok). 2007.